Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: NexStar Pharm(NXTR)

No earlier versions found for this Subject.

Return to NexStar Pharm(NXTR)

To all!

Carently, NXTR is priced at big discaunt comparing the Feb-Aug price. Recently Smith, Montgomery and Vector downgrade NXTR by lowering 1997/98 quoternaly and yearly EPS estimate. It's look like they are more concern about patent despute betwen NXTR-LIPO than real projection of worlwide and US sale of AmBisome and DaunoXome.

Even, with lower grow sale of AmBisome and DaunoXome, NXTR can easily than SEQU and LIPO accept price-war on market(smaler cost of sale and biger accont receivable), it is hard to explane lowering of EPS estimate.

Any other opinion or information on NXTR isue?

Miljenko